Application of CTRP13 in preparation of medicine for preventing and treating vascular and tumor diseases
A drug and disease technology, applied in the application field of CTRP13, can solve the problem that the effect of anti-tumor angiogenesis drugs needs to be improved and so on
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
experiment example 1
[0058] figure 1 Middle A is an 8-week-old male C57BL / 6 mouse, which was given control (Vehicle) and CTRP13-expressing adenovirus (CTRP13) respectively, injected into the tail vein of the mouse, and then the tumor cell suspension was subcutaneously inoculated on the back of the mouse. The size of the solid tumor was measured on the fifth day, ninth day, fourteenth day and sixteenth day after inoculation. figure 1 Middle B is the statistical chart of the change of tumor size in mice in A.
[0059] Depend on figure 1 In A and B, it can be seen that compared with the control treatment group, on the ninth day, fourteenth day, and sixteenth day after inoculation, the solid tumor volume of mice in the overexpression CTRP13 group decreased significantly, and overexpression CTRP13 inhibited the tumor growth.
[0060] Depend on figure 1 Middle C shows that the comparative effects of inhibiting CTRP13 and bevacizumab and sorafenib have been significantly improved.
experiment example 2
[0062] Eight-week-old male C57BL / 6 mice were given control (Vehicle) and CTRP13-overexpressed adenovirus (CTRP13) and subcutaneously inoculated tumors. The mice were sacrificed on the 16th day after inoculation, and the tumor tissues of the mice were collected and analyzed by immunofluorescence Technology detection of CD31 protein expression level.
[0063] figure 2 B is the immunofluorescence graph, CD31 protein expression, and related expression statistical graphs;
[0064] Depend on figure 2 It can be seen from the above results that the protein expression level of CD31 in tumor tissue was significantly decreased in subcutaneously transplanted tumors overexpressing CTRP13 group.
experiment example 3
[0066] After HUVEC cells were treated with solvent control, CTRP13, solvent control and adenovirus overexpressed CTRP13, the proliferation of HUVEC was detected by EdU assay.
[0067] image 3 Middle A is the solvent control group (Vehicle group) and CTRP13 treatment group (100ng / ml) using EdU assay to detect the proliferation of human umbilical vein endothelial cells (HUVEC). The first column is the solvent control group (Vehicle group), and the second column is the CTRP13 treatment group (CTRP13).
[0068] image 3 Middle B is the statistical graph of HUVEC proliferation detected by EdU experiment in solvent control group (Vehicle group) and CTRP13 treatment group (CTRP13).
[0069] Depend on image 3 In A and B, it can be seen that overexpression of CTRP13 inhibits the proliferation of HUVEC cells.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More